These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 21933588)

  • 1. Determinants for inadequate glycaemic control in Chinese patients with mild-to-moderate type 2 diabetes on oral antidiabetic drugs alone.
    Zhang SL; Chen ZC; Yan L; Chen LH; Cheng H; Ji LN
    Chin Med J (Engl); 2011 Aug; 124(16):2461-8. PubMed ID: 21933588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glycaemic control among patients with type 2 diabetes mellitus in seven European countries: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) study.
    Alvarez Guisasola F; Mavros P; Nocea G; Alemao E; Alexander CM; Yin D
    Diabetes Obes Metab; 2008 Jun; 10 Suppl 1():8-15. PubMed ID: 18435669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study.
    Moretto TJ; Milton DR; Ridge TD; Macconell LA; Okerson T; Wolka AM; Brodows RG
    Clin Ther; 2008 Aug; 30(8):1448-60. PubMed ID: 18803987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group trial conducted in russia.
    Ushakova O; Sokolovskaya V; Morozova A; Valeeva F; Zanozina O; Sazonova O; Zhadanova E; Starceva M; Kazakova E; Saifullina M; Shapiro I; Tarasov A; Al-Tayar B; Starkova N
    Clin Ther; 2007 Nov; 29(11):2374-84. PubMed ID: 18158078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of baseline characteristics, glycemic control and oral antidiabetic treatment in Asian patients with diabetes: The Registry for Assessing OAD Usage in Diabetes Management (REASON) Asia study.
    Vichayanrat A; Matawaran BJ; Wibudi A; Ferdous HS; Aamir AH; Aggarwal SK; Bajpai S
    J Diabetes; 2013 Sep; 5(3):309-18. PubMed ID: 23462227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved glycaemic control with BIAsp 30 in insulin-naïve type 2 diabetes patients inadequately controlled on oral antidiabetics: subgroup analysis from the IMPROVE study.
    Wenying Y; Benroubi M; Borzi V; Gumprecht J; Kawamori R; Shaban J; Shah S; Shestakova M; Ligthelm R; Valensi P;
    Curr Med Res Opin; 2009 Nov; 25(11):2643-54. PubMed ID: 19751116
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison.
    Wang JS; Lin SD; Lee WJ; Su SL; Lee IT; Tu ST; Tseng YH; Lin SY; Sheu WH
    Clin Ther; 2011 Dec; 33(12):1932-42. PubMed ID: 22078152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transferring to insulin detemir from NPH insulin or insulin glargine in type 2 diabetes patients on basal-only therapy with oral antidiabetic drugs improves glycaemic control and reduces weight gain and risk of hypoglycaemia: 14-week follow-up data from PREDICTIVE.
    Dornhorst A; Lüddeke HJ; Koenen C; Meriläinen M; King A; Robinson A; Sreenan S;
    Diabetes Obes Metab; 2008 Jan; 10(1):75-81. PubMed ID: 18034846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Profile and factors associated with glycaemic control of patients with type 2 diabetes in Greece: results from the diabetes registry.
    Souliotis K; Koutsovasilis A; Vatheia G; Golna C; Nikolaidi S; Hatziagelaki E; Kotsa K; Koufakis T; Melidonis A; Papazafiropoulou A; Tentolouris N; Siami E; Sotiropoulos A
    BMC Endocr Disord; 2020 Jan; 20(1):16. PubMed ID: 31992275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment Patterns and Glycemic Control in Older Adults with Type 2 Diabetes Mellitus Receiving Only Oral Antidiabetes Drugs in China.
    Zhang L; Ji L; Guo L; Lu J; Tian H; Zhu D; Xing X; Weng JP; Jia W
    Diabetes Technol Ther; 2015 Nov; 17(11):816-24. PubMed ID: 26448574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antidiabetic prescriptions and glycemic control in German patients with type 2 diabetes mellitus: a retrospective database study.
    Yurgin N; Secnik K; Lage MJ
    Clin Ther; 2007 Feb; 29(2):316-25. PubMed ID: 17472823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor linagliptin: a 4-week multicenter, randomized, double-blind, placebo-controlled phase IIa study in Japanese type 2 diabetes patients.
    Horie Y; Kanada S; Watada H; Sarashina A; Taniguchi A; Hayashi N; Graefe-Mody EU; Woerle HJ; Dugi KA
    Clin Ther; 2011 Jul; 33(7):973-89. PubMed ID: 21723606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of insulin glulisine as mono- or add-on therapy in patients with type 2 diabetes mellitus.
    Kawamori R; Iwamoto Y; Kadowaki T; Iwasaki M; Kim SW; Woo JT; Baik SH; Yoon KH
    Diabetes Obes Metab; 2009 Sep; 11(9):900-9. PubMed ID: 19614946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Initiation of insulin glargine therapy in type 2 diabetes subjects suboptimally controlled on oral antidiabetic agents: results from the AT.LANTUS trial.
    Davies M; Lavalle-González F; Storms F; Gomis R;
    Diabetes Obes Metab; 2008 May; 10(5):387-99. PubMed ID: 18355327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequency of glycated hemoglobin monitoring was inversely associated with glycemic control of patients with Type 2 diabetes mellitus.
    Fu C; Ji L; Wang W; Luan R; Chen W; Zhan S; Xu B
    J Endocrinol Invest; 2012 Mar; 35(3):269-73. PubMed ID: 21606668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin glargine provides greater improvements in glycaemic control vs. intensifying lifestyle management for people with type 2 diabetes treated with OADs and 7-8% A1c levels. The TULIP study.
    Blicklé JF; Hancu N; Piletic M; Profozic V; Shestakova M; Dain MP; Jacqueminet S; Grimaldi A
    Diabetes Obes Metab; 2009 Apr; 11(4):379-86. PubMed ID: 19087105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized controlled trial of the efficacy and safety of saxagliptin as add-on therapy in patients with type 2 diabetes and inadequate glycaemic control on metformin plus a sulphonylurea.
    Moses RG; Kalra S; Brook D; Sockler J; Monyak J; Visvanathan J; Montanaro M; Fisher SA
    Diabetes Obes Metab; 2014 May; 16(5):443-50. PubMed ID: 24205943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Association between side effects of oral anti-diabetic drugs and self-reported mental health and quality of life among patients with type 2 diabetes].
    Chen ZC; Zhang SL; Yan L; Wu MC; Chen LH; Ji LN
    Zhonghua Yi Xue Za Zhi; 2011 Jan; 91(4):229-33. PubMed ID: 21418865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing oral medication adherence among patients with type 2 diabetes mellitus treated with polytherapy in a developed Asian community: a cross-sectional study.
    Lee CS; Tan JHM; Sankari U; Koh YLE; Tan NC
    BMJ Open; 2017 Sep; 7(9):e016317. PubMed ID: 28912194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.